


Myocarditis following mRNA COVID-19 vaccination

Advisory Committee on Immunization Practices (ACIP)

July 19, 2022

Tom Shimabukuro, MD, MPH, MBA

CDC COVID-19 Vaccine Coordination Unit



cdc.gov/coronavirus

Topics

- Background on classic myocarditis and myocarditis associated with mRNA COVID-19 vaccination
- Update on myocarditis following mRNA COVID-19 vaccination with a focus on people ages 18 years and older
 - Vaccine Adverse Event Reporting System (VAERS)
 - Vaccine Safety Datalink (VSD)



Epidemiology of classic myocarditis (excluding infants)

- Usually has an infectious cause, typically viral or presumed to be viral, although infection with a pathogen is frequently not identified (only ~40% of time a pathogen is identified)^{1,2,3}
- Can be due to direct microbial infection of myocardial cells and/or ongoing inflammatory response, with or without clearance of pathogen^{4,5,6}
 - Can also be toxin-mediated or in setting of systemic infection or infection of non-cardiac tissue
- Rarer causes include autoimmune, hypersensitivity, and giant cell myocarditis
- Incidence in males > females starting after age 5 years⁷
- It is common to not identify a pathogen or possible infectious etiology for myocarditis
 - Based on case series, where autopsy tissues were examined and tissue-based infectious disease testing was performed, a specific infectious cause was only identified in 13%–36% of cases across age groups^{6,8,9}
 - For a case series where endomyocardial biopsy tissues were tested, viral nucleic acids were detected in heart tissues in ~38% (adults and children combined)¹




¹Bowles et al. J Am Coll Cardiol. 2003;42:466-72. ²Simpson et al. J Am Coll Cardiol. 2013;61:(10_Supplement) E1264. ³Park et al. J Korean Med Sci. 2021;36:e232. ⁴Caforio et al. Eur Heart J. 2013;34:2636-48, 2648a-2648d. ⁵Feldman et al. N Engl J Med. 2000;343:1388-98. ⁶Guarner et al. Hum Pathol. 2007;38:1412-9. ⁷Arola et al. J Am Heart Assoc. 2017;6:e005306. ⁸Weber et al. Arch Dis Child. 2008;93:594-8. ⁹Ilina et al. Pediatrics. 2011;128:e513-20.

Epidemiology of myocarditis

■ Children


- Annual incidence 0.8 per 100,000
 - In 15-18yo, 1.8 per 100,000 in 2015-2016
- 66% male
- Median LOS 6.1 days



Vasudeva et al. *American J Cardiology*. 2021.

■ Adults

- Gradual decrease in incidence with age
- 76% male



Kyto et al. *Heart*. 2013.

Previously presented: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/02-COVID-Oster-508.pdf>

LOS = Length of hospital stay Previously presented:

Characteristic	Myocarditis associated with mRNA COVID-19 vaccination ^{*,†}	Viral myocarditis [‡]
Inciting exposure	mRNA COVID-19 vaccination Dose 2 > Dose 1	Viral illness 30–60% with asymptomatic viral course
Demographics	Most cases in adolescents and young adults, males > females	Males > females, male incidence peaks in adolescence and gradually declines
Symptom onset	A few days after vaccination, most within a week	1–4 weeks after viral illness
Fulminant course	Rare [¶]	23%
ICU level support	~2%	~50%
Mortality/transplant	Rare [¶]	11–22%
Cardiac dysfunction	12%	60%
Recovery of cardiac function	Nearly all	~75%
Time to recovery of cardiac function (ejection fraction on cardiac echo), if initially poor	Hours to days	Days to weeks to months

* <https://www.cdc.gov/vaccines/acip/meetings/index.html>, <https://www.cdc.gov/vaccinesafety/research/publications/index.html>

† Oster et al. JAMA. 2022;327:331-340.

‡ Law et al. Circulation. 2021;144:e123-e135. Ghelani et al. Circ Cardiovasc Qual Outcomes. 2012;5:622-7. Kim et al. Korean Circ J. 2020;50:1013-1022. Messroghli et al. Am Heart J. 2017;187:133-144. Patel et al. J Am Heart Assoc. 2022;11:e024393.

¶ There are rare reports in the literature, especially from other countries, but it is unclear to what extent such cases were investigated



VAERS is the nation's early warning system for vaccine safety



VAERS

Vaccine Adverse Event Reporting System

<http://vaers.hhs.gov>



VAERS

VAERS accepts reports from everyone (healthcare professionals, patients, parents, caregivers, manufacturers, etc.) regardless of the plausibility of the vaccine causing the event or the clinical seriousness of the event

Key strengths

- Rapidly detects potential safety problems
- Can detect rare adverse events

Key limitations

- Passive surveillance system
- Inconsistent quality and completeness of information
- Reporting biases
- Generally, cannot determine cause and effect ←



U.S. reports to VAERS of myocarditis after mRNA COVID-19 vaccination among people ages 18 years and older following primary series and 1st booster

(as of May 26, 2022)

- Approximately **491.9 million** primary series and 1st booster mRNA COVID-19 vaccine doses administered in the United States among people ages 18 years and older
 - 213.3 million dose 1
 - 185.1 million dose 2
 - 93.4 million 1st booster dose

Preliminary reports of myocarditis (N=1836)

Under review*
(n=11)

Did not meet definition†
(n=504)


Met CDC definition†
(n=1321)

* Awaiting medical records and/or healthcare provider interview; some still processing

† Adjudicated after healthcare provider interview and/or medical record review, or vaccine received before authorized for use; CDC myocarditis case definition available at: <https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm>



Verified* U.S. reports to VAERS of myocarditis after mRNA COVID-19 vaccination among people ages 18 years and older following primary series and 1st booster, by time to symptom onset[†] and dose number (N=1184; as of May 26, 2022)



[†] 1184 of 1321 (90%) with known time to symptom onset; 183 (15%) reports with time to symptom onset >10 days



*Verified according to CDC myocarditis case definition available at: <https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm>

Verified U.S. reports to VAERS of myocarditis after mRNA COVID-19 vaccination among people ages 18 years and older following primary series and 1st booster

(as of May 26, 2022, 491.9 million primary series and 1st booster doses administered)

- 1321 reports verified using CDC case definition
 - Median age: 28 years (IQR: ages 21–42 years)
 - Median time to symptom onset after vaccination: 3 days (IQR: 2–5 days)
 - 229/1184 (19%) reports with known symptom onset >7 days after vaccination
 - After dose 2 (n=962), dose 1 (n=257), 1st booster dose (n=102)
 - Male cases (n=960), female cases (n=361)



VAERS reporting rates of myocarditis (per 1 million doses administered) after mRNA COVID-19 vaccination, days 0–7 and 8–21 post-vaccination^{*,†}

		0–7 days			8–21 days			0–7 days			8–21 days		
		Males			Males			Females			Females		
Age (yrs)		Dose 1	Dose 2	Booster	Dose 1	Dose 2	Booster	Dose 1	Dose 2	Booster	Dose 1	Dose 2	Booster
Pfizer-BioNTech	5–11	0.2	2.6	0.0	0.6	0.0	0.0	0.2	0.7	0.0	0.2	0.0	0.0
	12–15	5.3	46.4	15.3	1.2	1.2	0.9	0.7	4.1	0.0	0.4	0.2	0.9
	16–17	7.2	75.9	24.1	1.7	3.2	1.3	0.0	7.5	0.0	0.7	0.4	0.0
Pfizer-BioNTech and Moderna	18–24	4.2	38.9	9.9	1.1	2.2	0.4	0.6	4.0	0.6	0.2	0.7	0.0
	25–29	1.8	15.2	4.8	0.4	1.1	0.5	0.4	3.5	2.0	0.2	0.0	0.8
	30–39	1.9	7.5	1.8	0.4	0.8	0.2	0.6	0.9	0.6	0.3	0.2	0.0
	40–49	0.5	3.3	0.4	0.2	0.5	0.0	0.4	1.6	0.6	0.2	0.2	0.0
	50–64	0.5	0.7	0.4	0.2	0.3	0.1	0.6	0.5	0.1	0.2	0.5	0.1
	65+	0.2	0.3	0.6	0.3	0.2	0.1	0.1	0.5	0.1	0.1	0.2	0.1

* As of May 26, 2022; reports verified to meet case definition by provider interview or medical record review; primary series and 1st booster doses only

† An estimated 1–10 cases of myocarditis per 100,000 person years occurs among people in the United States, regardless of vaccination status; adjusted for days 0–7 and 8–21 risk intervals, this estimated background is **0.2 to 2.2 per 1 million person-day 0–7 risk interval** and **0.4 to 3.8 per 1 million person-day 8–21 risk interval** (peach shaded cells indicate that reporting rate exceeded estimated background incidence for the period)



CDC enhanced surveillance for myocarditis outcomes following mRNA COVID-19 vaccination in VAERS case reports among people ages 12–29 years^{*,†}

- **Purpose:** Assess functional status and clinical outcomes among individuals reported to have developed myocarditis after mRNA COVID-19 vaccination
- **Methods:** A two-component survey conducted at least 90 days after the onset of myocarditis symptoms
 - Patient survey: Focused on ascertaining functional status, clinical symptoms, quality of life, and need for medication or other medical treatment
 - Healthcare provider (e.g., cardiologist): Gather data on cardiac health and functional status



* <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myo-outcomes.html>

† Previous presentation available at: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-02-04/04-COVID-Kracalic-508.pdf>

CDC enhanced surveillance for myocarditis outcomes following mRNA COVID-19 vaccination in VAERS case reports among people ages 12–29 years

Results of cardiologist/healthcare provider survey

- Based on the cardiologists or healthcare provider assessment, most patients appear to have fully or probably fully recovered from their myocarditis
 - 398 patients received a follow-up assessment by a cardiologist or other healthcare provider regarding their myocarditis recovery

81.7% fully recovered
or probably fully
recovered

- **265 (66.6%) fully recovered**
- **60 (15.1%) probably fully recovered but awaiting more information**
- 61 (15.3%) improved but not fully recovered
- 8 (2.0%) recovery status unsure
- 4 (1.0%) same cardiac status as at initial myocarditis diagnosis



CDC enhanced surveillance for myocarditis outcomes following mRNA COVID-19 vaccination in VAERS case reports among people ages 12–29 years

Key findings

- At least 90 days after myocarditis diagnosis, most patients who were reached reported no impact on their quality of life, and most did not report missing school or work
- Most (81.7%) healthcare providers who completed surveys indicated the patient was fully recovered or probably fully recovered
 - There was substantial heterogeneity in initial and follow-up treatment and testing
 - There did not appear to be a single test that was indicative of recovery

Next steps

- Additional follow-up with patients who were not yet recovered at time of the 90+ day survey (and their healthcare providers) to further assess recovery status at 12+ months
- Follow-up and evaluation of myocarditis cases in children ages 5–11 years is ongoing





VSD Rapid Cycle Analysis (RCA)

Aims

- To monitor the safety of COVID-19 vaccines weekly using pre-specified outcomes of interest among VSD members
- To describe the uptake of COVID-19 vaccines over time among eligible VSD members overall and in strata by age, site, and race/ethnicity

VSD COVID-19 vaccine RCA prespecified surveillance outcomes

Prespecified outcomes	Settings
Acute disseminated encephalomyelitis	Emergency dept, Inpatient
Acute myocardial infarction – First ever in EHR in ICD-10 era	Emergency dept, Inpatient
Acute respiratory distress syndrome	Emergency dept, Inpatient
Anaphylaxis – First in 7 days in EHR in ICD-10 era	Emergency dept, Inpatient
Appendicitis	Emergency dept, Inpatient
Bell's palsy – First ever in EHR in ICD-10 era	Emergency dept, Inpatient, Outpatient
Cerebral venous sinus thrombosis	Emergency dept, Inpatient
Disseminated intravascular coagulation	Emergency dept, Inpatient
Encephalitis / myelitis / encephalomyelitis	Emergency dept, Inpatient
Guillain-Barré syndrome	Emergency dept, Inpatient
Immune thrombocytopenia	Emergency dept, Inpatient, Outpatient
Kawasaki disease	Emergency dept, Inpatient
Multisystem inflammatory syndrome in children/adults (MIS-C/MIS-A)	Emergency dept, Inpatient
Myocarditis / pericarditis – First in 60 days in EHR in ICD-10 era	Emergency dept, Inpatient
Narcolepsy / cataplexy	Emergency dept, Inpatient, Outpatient
Pulmonary embolism – First ever in EHR in ICD-10 era	Emergency dept, Inpatient
Seizures	Emergency dept, Inpatient
Stroke, hemorrhagic	Emergency dept, Inpatient
Stroke, ischemic	Emergency dept, Inpatient
Thrombosis with thrombocytopenia syndrome – First ever in EHR in ICD-10 era	Emergency dept, Inpatient
Thrombotic thrombocytopenic purpura	Emergency dept, Inpatient
Transverse myelitis	Emergency dept, Inpatient
Venous thromboembolism – First ever in EHR in ICD-10 era	Emergency dept, Inpatient, Outpatient


VSD RCA analytic strategy

- For the primary analysis, the number of outcomes observed in the risk interval after COVID-19 vaccination were compared to the number expected
- The expected was derived from “vaccinated concurrent comparators” who were in a comparison interval after COVID-19 vaccination
- On each day that an outcome occurred, vaccinees who were in their risk interval were compared with similar vaccinees who were concurrently in their comparison interval
 - Comparisons were adjusted for age group, sex, race/ethnicity, VSD site, as well as calendar date
- For the pre-specified outcome myocarditis/pericarditis, cases were verified using the CDC case definition (<https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm>)




mRNA COVID-19 vaccine doses administered in VSD in people ages 18–39 years by week

PRIMARY SERIES doses administered to 18-39-year-olds by week




BOOSTER doses administered to 18-39-year-olds by week



Note: Data shown on slide are from December 14, 2020 – May 21, 2022



Day of onset of verified myocarditis/pericarditis among people ages 18–39 years after either primary series dose of a mRNA COVID-19 vaccine



Verified myocarditis and pericarditis in the 0–7-day Risk Interval among 18–39-year-old MALES by product and dose

(compared with outcome events in vaccinated comparators on the same calendar days)

		Analysis					
Vaccine	Dose	Events in Risk Interval	Events in Comparison Interval*	Adjusted Rate Ratio†	95% Confidence Interval	2-sided P-value	Excess cases in Risk Period per million doses
Either mRNA COVID-19 Vaccine**	Dose 1	11	18	2.10	0.86 – 4.97	0.101	5.1
	Dose 2	59	11	14.51	7.54 – 29.88	<0.001	50.6
	Booster	18	5	7.53	2.66 – 24.53	<0.001	29.5
Pfizer-BioNTech (primary)	Dose 1	5	12	1.91	0.56 – 5.87	0.279	3.4
	Dose 2	32	7	13.98	6.01 – 36.14	<0.001	44.1
Pfizer-BioNTech (booster)	Booster	10	2	13.72	2.86 – 104.20	<0.001	32.3
Moderna (primary)	Dose 1	6	6	2.41	0.63 – 9.24	0.193	8.2
	Dose 2	27	3	23.46	7.49 – 100.76	<0.001	62.7
Moderna (booster)	Booster	5	2	4.56	0.82 – 36.56	0.085	21.5

* Comparison interval is 22–42 days after either primary series or booster dose

† Adjusted for VSD site, 5-year age group, sex, race/ethnicity, and calendar date

** Individual product events may not sum to “Either mRNA COVID-19 Vaccine” total due to heterologous series and/or noninformative events.



Verified myocarditis and pericarditis in the 0–7-day Risk Interval among 18–39-year-old FEMALES by product and dose

(compared with outcome events in vaccinated comparators on the same calendar days)

		Analysis					
Vaccine	Dose	Events in Risk Interval	Events in Comparison Interval*	Adjusted Rate Ratio [†]	95% Confidence Interval	2-sided P-value	Excess cases in Risk Period per million doses
Either mRNA COVID-19 Vaccine**	Dose 1	3	2	5.36	0.70 – 50.71	0.105	1.8
	Dose 2	6	1	22.08	3.10 – 530.11	<0.001	4.4
	Booster	4	3	2.68	0.54 – 14.85	0.227	3.4
Pfizer-BioNTech (primary)	Dose 1	1	1	5.44	0.14 – 213.88	0.312	1.0
	Dose 2	5	1	19.85	2.59 – 495.35	0.002	5.9
Pfizer-BioNTech (booster)	Booster	1	2	0.98	0.03 – 12.91	0.976	-0.05
Moderna (primary)	Dose 1	2	1	3.86	0.27 – 120.68	0.325	2.9
	Dose 2	1	0	NE	0.33 - ∞	0.136	2.0
Moderna (booster)	Booster	1	1	2.48	0.06 – 105.24	0.591	6.9

NE= not estimable

* Comparison interval is 22–42 days after either primary series or booster dose

** Individual product events may not sum to “Either mRNA COVID-19 Vaccine” total due to heterologous series and/or noninformative events.

[†] Adjusted for VSD site, 5-year age group, sex, race/ethnicity, and calendar date



VSD incidence rates of verified myocarditis/pericarditis 0–7 days following mRNA COVID-19 vaccination – December 14, 2020–March 31, 2022

(Adults ages 18–39 years)	Pfizer-BioNTech			Moderna		
	Cases, 0–7 days	Doses	Incidence rate per million doses admin	Cases, 0–7 days	Doses	Incidence rate per million doses admin
18–29 years						
Males – Dose 1	4	348,080	11.5	5	207,073	24.1
Males – Dose 2	27	330,594	81.7	19	195,333	97.3
Males – 1st Booster	7	146,979	47.6	7	99,551	70.3
Females – Dose 1	1	414,730	2.4	1	253,773	3.9
Females – Dose 2	2	398,678	5.0	0	242,887	0.0
Females - 1st Booster	1	212,299	4.7	2	143,728	13.9
30–39 years						
Males – Dose 1	1	352,403	2.8	1	223,064	4.5
Males – Dose 2	5	340,819	14.7	8	216,280	37.0
Males – 1st Booster	3	182,162	16.5	1	140,133	7.1
Females – Dose 1	0	420,934	0.0	1	265,362	3.8
Females – Dose 2	3	409,651	7.3	1	259,360	3.9
Females - 1st Booster	1	247,245	4.0	2	180,199	11.1

Verified myocarditis and pericarditis 0–7 days after any primary series dose of mRNA COVID-19 vaccine: Level of care and status by age group/product

Level of care and status	18–39-year-olds (Pfizer-BioNTech) N=43	18–39-year-olds (Moderna) N=35
Highest level of care		
Emergency department	5 (12%)	6 (17%)
Admitted to hospital	37 (86%)	29 (83%)
Admitted to ICU	1 (2%)	0 (0%)
Length of hospital stay, median (range)	1 day (0–2 days)	1 day (0–13 days)
0–1 days	24 (56%)	23 (66%)
2–3 days	19 (44%)	11 (31%)
4+ days	0 (0%)	1 (3%)
Discharged to home	43 (100%)	35 (100%)

Verified myocarditis and pericarditis 0-7 days after 1st booster dose of mRNA COVID-19 vaccine: Level of care and status by age group/product

Level of Care and Status	18–39-year-olds (Pfizer-BioNTech) N=23	18–39-year-olds (Moderna) N=12
Highest level of care		
Emergency department	4 (17%)	2 (17%)
Admitted to hospital	18 (78%)	9 (75%)
Admitted to ICU	1 (4%)	1 (8%)
Length of hospital stay, median (range)	1 day (0–3 days)	1 days (0–2 days)
0–1 days	17 (74%)	9 (75%)
2–3 days	6 (26%)	3 (25%)
4+ days	0 (0%)	0 (0%)
Discharged to home	23 (100%)	12 (100%)

Summary: Myocarditis and pericarditis following mRNA COVID-19 vaccination

- Current evidence supports a causal association between mRNA COVID-19 vaccination and myocarditis and pericarditis
- Myocarditis is a rare event following mRNA COVID-19 vaccination
 - CDC verified 1321 myocarditis case reports in people ages 18 years and older after 491.9 million mRNA COVID-19 primary series and booster vaccinations administered in this age group in the United States
- Cases following mRNA COVID-19 vaccination cluster within the first week of vaccination
- Risk is greatest in adolescents and young adults, higher after dose 2 compared to dose 1 of the primary series, and higher in males compared to females
 - Some risk estimates for females in VSD are comparable to males but case counts are small and excess risk in females is substantially lower than for males
- Risk appears to decrease with age and the male to female predominance of cases attenuates with age
- Reporting rates in VAERS are highest following dose 2; reporting rates following dose 1 and 1st booster dose tend to be lower
- Incidence rates in VSD of verified myocarditis/pericarditis 0–7 days following mRNA COVID-19 vaccination are generally highest following dose 2
- Available information suggests that most persons with myocarditis after mRNA COVID-19 vaccination recover from myocarditis by 3–8 months after diagnosis



Acknowledgments

- VAERS Team
- Clinical Immunization Safety Assessment (CISA) Project
- Vaccine Safety Datalink (VSD) Team
- CDC MOVING Team
- CDC Immunization Safety Office
- CDC Infectious Diseases Pathology Branch
- COVID-19 Vaccine Task Force Data Monitoring and Reporting Group
- FDA/Center for Biologics Evaluation and Research
- Kaiser Permanente Northern California (VSD)
- Marshfield Clinic Research Institute (VSD)
- VSD sites
 - HealthPartners Institute, Minneapolis, MN
 - Kaiser Permanente Colorado, Denver, CO
 - Kaiser Permanente Northwest, Portland, OR
 - Kaiser Permanente Southern California, Los Angeles, CA
 - Kaiser Permanente Washington, Seattle, WA
 - Denver Health, Denver, CO




Disclaimer

- The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC) or the U.S. Food and Drug Administration (FDA)
- Mention of a product or company name is for identification purposes only and does not constitute endorsement by CDC or FDA



Thank you!



For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

